Heston, Margo B.
Hanslik, Kendra L.
Zarbock, Katie R.
Harding, Sandra J.
Davenport-Sis, Nancy J.
Kerby, Robert L.
Chin, Nathaniel
Sun, Yi
Hoeft, Ana
Deming, Yuetiva
Vogt, Nicholas M.
Betthauser, Tobey J.
Johnson, Sterling C.
Asthana, Sanjay
Kollmorgen, Gwendlyn
Suridjan, Ivonne
Wild, Norbert
Zetterberg, Henrik
Blennow, Kaj
Rey, Federico E.
Bendlin, Barbara B.
Ulland, Tyler K.
Funding for this research was provided by:
National Institute of General Medical Sciences (T32GM081061)
Geriatrics Research, Education, and Clinical Center of William S. Middleton Memorial Veterans Hospital
National Institute on Aging (R01AG062285, R01AG070973)
Swedish Research Council (2018-02532, 2017-00915)
European Research Council (681712)
Swedish State Support for Clinical Research (ALFGBG-71320, ALFGBG-715986)
Alzheimer's Drug Discovery Foundation (201809-2016862, RDAPB-201809-2016615)
AD Strategic Fund and Alzheimer's Association (ADSF-21-831376-C)
Olav Thon Foundation
Erling-Persson Family Foundation
Stiftelsen för Gamla Tjänarinnor (FO2019-0228)
European Union Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie (860197)
UK Dementia Research Institute at University College London
Swedish Alzheimer Foundation (AF-742881)
Swedish Brain Foundation (FO2017-0243)
European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236)
National Institutes of Health (R01AG068398)
Wisconsin Partnership Program
USDA National Institute of Food and Agriculture, Hatch project (WIS03073)
Article History
Received: 25 April 2023
Accepted: 25 October 2023
First Online: 14 November 2023
Competing interests
: Roche Diagnostics International Ltd (Rotkreuz, Switzerland) provided CSF testing equipment and analysis for Drs. Bendlin and Johnson. COBAS, COBAS E, and ELECSYS are trademarks of Roche. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders. It is used for research purposes only and is not approved for clinical use. MBH declares no competing interests. KLH declares no competing interests. KRZ declares no competing interests. SJH declares no competing interests. NJD declares no competing interests. RLK declares no competing interests. YS declares no competing interests. AH declares no competing interests. YD declares no competing interests. NMV declares no competing interests. TJB declares no competing interests. SCJ has received grant funding from Cerveau and consultant fees from Roche Diagnostics, Merck, and ALZpath outside the submitted work. GK is a full-time employee of Roche Diagnostics GmbH. IS is a full-time employee and shareholder of Roche Diagnostics International Ltd. NW is a full-time employee of Roche Diagnostics GmbH. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. BBB has received precursor and imaging agents from AVID radiopharmaceuticals. FER declares no competing interests. TKU declares no competing interests.